Compares two treatments for chronic inflammatory demyelinating polyneuropathy in adults
Compares immunoadsorption with immunoglobulins in adults with CIDP not helped by steroids.
Plain-language title generated from the registry record
Registry title: Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Key facts
- Where
- Ulm, GermanySee the site
- Phase
- Phase 2
Where in Germany
- Department of Neurology, University of UlmUlm, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Ulm
- Trial code
- NCT04881682
- Record updated
- 1 May 2026
- Original description
This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).Read full original descriptionShow less
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Inclusion: Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines; Disease duration of 3 years or less; Age 18 years or above; Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician.
Exclusion: Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment; Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg/l, or evidence of nitrite-positive urinary tract infection; immunoglobulin A deficiency; Other contraindications against immunoadsorption or intravenous immunoglobulins.